OBJECTIVE： To investigate the influence of CYP3A5*3（rs776746） genetic polymorphism on blood concentration of tacrolimus （TAC） and renal function in renal transplant recipients during the stable period. METHODS： A total of 98 renal transplant recipients during the stable period receiving TAC-based triple anti-rejection scheme （TAC+sodium mycophenol+prednisone acetate） after surgery and regular follow-up were selected from our hospital during Jan. 1995-Dec. 2014. The follow-up information during Jan.-Dec. 2016 was also collected. Trough concentration of TAC in renal transplant recipients was determined by chemiluminescence microparticle immuno assay. Standard blood concentration （C/D） was calculated after corrected with body weight and daily dose. Scr level was detected with dry chemistry method. CYP3A5*3 genotype was detected by PCR-RFLP and direct sequencing. The relationship of CYP3A5*3 genetic polymorphism with TAC C/D value and Scr level was determined by Kruskal Wallis H or Mann-Whitney U assay.  RESULTS： Among 98 renal transplant recipients， there were 9 cases of CYP3A5*3 *1/*1（AA） genotype， 37 cases of *1/*3（AG） genotype and 52 cases of *3/*3（GG）genotype. The gene frequencies were 9.18％， 37.76％， 53.06％， which were all in line with Hardy-Weinberg equilibrium （P＞0.05）. There was no statistical significance in trough concentration of TAC among different genotypes （P＞0.05）. There was statistical significance in TAC dose and C/D value among different genotypes （P＞0.05）. TAC dose of CYP3A5*3 *3/*3 genotype recipients was significantly lower than those of *1/*3 and *1/*1 genotype recipients； that of *1/*3 genotype recipients was significantly lower than that of *1/*1 genotype recipients. C/D value of *3/*3 genotype recipients was significantly higher than those of *1/*3 and *1/*1 genotype recipients； that of *1/*3 genotype recipients was significantly higher than that of *1/*1 genotype recipients， with statistical significance （P＜0.05）. There was no statistical significance in Scr levels among different genotypes （P＞0.05）. CONCLUSIONS： CYP3A5*3 genetic polymorphism significantly influences blood concentration of TAC in renal transplant recipients during the stable period， and *3 allele carriers have higher C/D values and need smaller TAC daily dose. CYP3A5*3 genetic polymorphism may be not associated with Scr level.